Stifel Reiterates Acadia Pharmaceuticals (ACAD) at Hold, Key Question Remains Whether sNDA for pimavanserin Will be Approved in ADP
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Hold rating and $20.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
